ADCT — ADC Therapeutics SA
Is ADCT overbought or oversold? Here is the current MarketMoodz read.
ADC Therapeutics SA (ADCT) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $1.25. The rating moved from Oversold to Strong Oversold on November 14, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$1.25
- Last changeMoved from Oversold to Strong Oversold on November 14, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
ADC Therapeutics SA (ADCT) is a clinical-stage ADC specialist whose near-term trajectory is dominated by clinical readouts, cash runway dynamics and partnership possibilities. The company’s ADC platform is a meaningful competitive asset, but limited current revenues and a challenging small‑cap biotech financing backdrop raise dilution and execution risk. Market sentiment is favoring large-cap pharma and defensive healthcare exposure, which dampens investor appetite for binary oncology names; absent clear positive clinical/newsflow or non-dilutive financing, expect continued volatility and downward pressure over the coming weeks.
Key factors
- Clinical-stage biotech with revenue exposure limited; valuation driven primarily by trial readouts and partner deals
- Technology focus on antibody-drug conjugates (ADCs) provides differentiated therapeutic opportunity versus small molecules and biologics
- Near-term financial health likely dependent on cash runway, financing/dilution events, and potential partner/licensing agreements
- Sector flows favor large-cap pharma and defensive names, reducing investor appetite for small-cap, binary biotech stories
- Convertible-debt and broader biotech financing environment raise probability of dilution or costly hedging for mid-cap biotechs
Risks
- Clinical trial setbacks or negative readouts that could materially reduce valuation
- Limited cash runway requiring dilutive equity raises or asset sales under adverse terms
- Regulatory delays or requests for additional data increasing time-to-market and development costs
- Competitive pressure from larger pharma ADC programs and alternative oncology modalities
- Manufacturing and supply-chain complexity for ADCs leading to delays or higher-than-expected costs
- Thin trading liquidity and low retail attention increasing volatility and potential downside on negative news
See today's live rating, score and targets
Members see the live hourly rating for ADCT — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.